| Date | Title | Description |
| 01.11.2024 | Labroots to Host 15th Annual Clinical Diagnostics & Research Virtual Event Series on November 13th, 2024 | Labroots 2024 Clinical Diagnostics & Research Virtual Event November 13th
Exploring fascinating observations in clinical diagnostics & research and how it has become a pivotal scientific discipline built on cutting-edge research des... |
| 20.09.2024 | Navigating the Frontiers of Cancer Research: The 12th Annual Virtual Event by Labroots | The fight against cancer is a relentless battle. Each year, researchers and medical professionals gather to share insights, breakthroughs, and strategies. On October 2, 2024, Labroots will host its 12th Annual Cancer Research & Oncology... |
| 19.09.2024 | Labroots to Host the 12th Annual Cancer Research & Oncology Virtual Event Series on October 2nd, 2024 | Labroots 2024 Cancer Research & Oncology Virtual Event October 2nd
Exploring innovations in cancer & oncology research is an essential scientific discipline that conducts cutting-edge research for global cancer prevention, diagnosis... |
| 26.07.2024 | Brief: SCiFi Foods assets up for sale in online auction August 6-8 | An online auction for the assets of San Leandro-based cultivated meat startup SCiFi Foods will be held on August 6-8.
According to auctioneer Silicon Valley Disposition, “The auction features extremely high-end and late-model (mostly 2022) ... |
| 28.05.2024 | Accelerate Early-Phase Biologics from the Clinic to Commercialization: Key Technologies & Strategies in Cell-Based Manufacturing, Upcoming Webinar with Abzena & Sartorius | www.abzena.com
In this free webinar, learn about key strategies that speed upaccelerate monoclonal antibody (mAbs) products and therapies from the clinic to commercial scale-up. These include employing fully integrated end-to-end single-use... |
| 13.03.2024 | $76.6+ Bn Cell Cryopreservation Market to Grow at CAGR of 22.2% , Globally, by 2031 | https://www.alliedmarketresearch.com/cell-cryopreservation-market-A11917
PORTLAND, OREGON, UNITED STATES, March 13, 2024 /EINPresswire.com/ -- 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐚 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐭𝐢𝐭𝐥𝐞𝐝, "𝐂𝐞𝐥𝐥 𝐂𝐫𝐲𝐨𝐩𝐫𝐞𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐛𝐲 ...... |
| 08.03.2024 | Fetal Bovine Serum Market Size, Share And Growth Analysis For 2024-2033 | The Business Research Company's Fetal Bovine Serum Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
The Business Research Company's Fetal Bovine Serum Global Market Report 2024 – Market Size, Trends, And Global... |
| 08.03.2024 | Global Bioprocess Bags and Containers Market Report 2024-2033: Focus on Application, End-user, Product Type, and 12+ Countries | - |
| 05.03.2024 | Baculovirus Expression System Market projected to reach USD 522.7 Million by 2030, growing at a CAGR of 7.5% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study | - |
| 08.07.2023 | Life Science Factory to Open a New Location at Helmholtz Munich in 2024 | The Life Science Factory incubator initiated by Sartorius in Göttingen and the top biomedical research center Helmholtz Munich are entering into a strategic partnership to support spin-offs in the life sciences. Within this framework, the L... |
| 05.06.2023 | Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing | News Summary:
Integration of Sartorius' process scale multi-column chromatography with Waters' process analytical technology to provide robust analytical data for downstream biomanufacturing of mAbs, recombinant proteins, vaccines, and othe... |
| 24.05.2023 | Virus Filtration Market Size Likely to be valued at US$ 12.92 Billion by 2030 | Wuxi Biologics, Clean Cell, Sartorius AG | Virus Filtration Market
"Virus filtration also helps to optimize process economics and prevents the loss of valuable products"
The global virus filtration market was valued at US$ 4,441.2 Mn in 2022 and is forecast to reach a valu... |
| 26.01.2023 | Preliminary results 2022 of Sartorius Stedim Biotech | Sales revenue of 3,493 million euros, in constant currencies1 up 13.2 percent organically1 and up 15.1 percent including acquisitions (reported: up 21.0 percent) Underlying EBITDA1 at 1,221 million euros, resulting margin at 35.0 percent As... |
| 26.01.2023 | Sartorius with clear double-digit growth in fiscal 2022 | Preliminary figures for 2022: Sales revenue up 15.0 percent in constant currencies, underlying EBITDA up 20.0 percent, underlying EBITDA margin at 33.8 percent Both divisions with double-digit growth; strong performance of Lab Products &... |
| 31.03.2022 | NORTHWEST ANALYTICS AND SARTORIUS ANNOUNCE PARTNERSHIP TO DELIVER ADVANCED ANALYTICS SOLUTIONS | Northwest Analytics
Announcing a new partnership that will expand single-source, real-time analytics methodologies available to manufacturers.
...The partnership between Northwest Analytics and Sartorius means we have the opportunity to ope... |
| 21.03.2022 | Process Spectroscopy Market to Cross USD 2,080.9 Mn Valuation by 2027 | Sartorius AG, Foss A/S, ABB Ltd., Shimadzu | NEW JERSEY, UNITED STATES, March 21, 2022 /EINPresswire.com/ -- Description
New Research Study ""Process Spectroscopy Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment O... |
| 10.03.2022 | Microbial Air Monitoring Facilitates Disease Surveillance and Outbreak Response, Upcoming Webinar Hosted by Xtalks | Early identification of pathogens and variants of concern allows for timely implementation of mitigation strategies and informs vaccine development.
TORONTO (PRWEB) March 10, 2022
SARS-CoV-2 spreads through airborne transmission. Aerosols c... |
| 27.01.2022 | Sartorius closes fiscal 2021 with 50 percent growth and a jump in profitability | GÖTTINGEN, Germany, Jan. 27, 2022 /PRNewswire/ -- Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 ... |
| 27.01.2022 | Preliminary results 2021 of Sartorius Stedim Biotech | AUBAGNE, France, Jan. 27, 2022 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, closed fiscal 2021 with exceptionally strong growth and a jump in profitability due to the excellent development of its co... |
| 11.01.2022 | Sartorius AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] | DGAP Preliminary announcement financial reports: SARTORIUS AG / Preliminary announcement on the disclosure of financial statements
Sartorius AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115... |
| 25.11.2021 | Sartorius Stedim Biotech : significantly expands activities in South Korea | Press Release
Göttingen, November 25, 2021
Sartorius significantly expands activities in South Korea
The life science company Sartorius is investing around 270 million euros, some 300 million U.S. dollars, through the end of 2024 in expandi... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | John Maraganore isn’t wasting any time shifting to a new post-Alnylam phase in his long biotech career. Startup wunderkind Beam Therapeutics has lured the soon-to-be ex-CEO to its board, where Maraganore can begin to play godfather to the n... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | One of the major reasons the FDA’s accelerated approval pathway receives so many accolades and so much support is that it speeds new and hopefully improved drugs to patients, usually in oncology, while confirmatory ... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | Johnson & Johnson is quietly rolling out a new ad campaign on social media posts and in an introductory video on its YouTube channel.
With the tagline “World of Well,” the online video talks about building a future where cancers can be ... |
| 09.11.2021 | Low-profile eye drop developer spells out the game plan that drew Brent Saunders to the board — and it involves going earlier than anti-VEGFs | When Brent Saunders took on the chairman role on OcuTerra Therapeutics’ board of directors a few months ago — his first biotech gig since selling Allergan to AbbVie — he drew attention to a startup that wasn’t quite ready fo... |
| 09.11.2021 | Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms | UK biotech Compass Pathways revealed this morning that they reached the primary endpoint in a Phase IIb clinical trial of psilocybin therapy.
In the randomized, controlled and double-blind trial, investigators looked ... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | Clinical trials have a diversity problem. That’s the opening statement on Abbott’s new website to promote its latest diversity efforts — and the reason why it’s laying out concrete steps for change.
While lack of diversity isn’t exactly sho... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | Abercrombie & Fitch’s Andy Kennemer was getting ready for the Super Bowl of retail, better known as Black Friday, a few years ago when a recruiter for GlaxoSmithKline reached out. Kennemer, then Abercrombie’s VP of marketing, was preppi... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | FerGene’s $570 million implosion evidently hasn’t scared off Blackstone from cell and gene therapy.
The massive Wall Street investment firm announced early Monday a deal to invest up to $250 million in Autolus, a UK biotech that raised hund... |
| 09.11.2021 | Looking to get ahead in a packed migraine market, Amgen touts head-to-head data for Aimovig | A year after Amgen announced its injectable migraine prevention drug Aimovig proved a better option than the widely used treatment topiramate in a head-to-head study, the pharma company is rolling out the full data. But wi... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | In the year and a half since Biohaven landed an FDA approval for Nurtec, the New Haven-based biotech has worked hard to overcome what it called “perhaps the greatest challenge of any new drug launch with the emergence of the pandemic” to bo... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | Immatics has scored a significant advance in its quest to develop cell therapies for solid tumors.
Tuesday morning the biotech — based in Germany with a big operation in Houston — took the wraps off a set of promising preliminary data from ... |
| 09.11.2021 | Covid-19 roundup: AstraZeneca launches new virus R&D division; US buys more of Merck's antiviral pill | AstraZeneca is launching a new division to encompass its vaccine and antibodies businesses.
The subunit will focus on its Covid-19 vaccine and long-acting antibody combination, a company spokesperson told Endpoints ... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | Five months after the approval of Biogen’s Aduhelm, the bad news just keeps piling up for the Alzheimer’s drug. The confirmation yesterday of a Biogen investigation into the death of trial participant is the latest setback, but it adds to a... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | Zhen Su’s love for T cells — which he compares to his high school sweetheart — began long before he took over the oncology development group at Merck KGaA.
But it was at the German pharma giant that he oversaw the development of Bavencio, i... |
| 09.11.2021 | Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company | After Sigilon Therapeutics’ $126 million IPO last December, COO Devyn Smith started getting calls. Job offers, mostly, for this biotech or that, none that quite hit.
Then a recruiter reached out about an opening at a spinout... |
| 09.11.2021 | China's Zai Lab spins 2 more licensing deals, including a sudden dive into neuroscience | China cancer specialist Zai Lab has made its name in-licensing Western drugs and using its deep knowledge of the East Asian market to churn out results. The biotech has now signed two more licensing deals for a trio of drugs, i... |
| 09.11.2021 | UPDATED: Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal | A centerpiece of Novartis’ $2.5 billion bispecifics deal with Xencor has been sidelined, the California biotech said in its third quarter earnings report Monday.
Novartis terminated its ex-US rights to the program dubbe... |
| 09.11.2021 | Accelerated approvals under fire again as pivotal trials typically take about as long as confirmatory trials, research shows | About two years ago, Majid Jafar, CEO of the 50-year-old Emirati oil firm Crescent Petroleum, found himself with a problem of his own making, one that he was happy to have.
In 2014, Jafar and his wife, Lynn Barghout Jafar, had a daughter, A... |
| 08.11.2021 | Small biotech chaired by ex-Purdue CEO Mark Timney jumps into the SPAC lane | The latest biotech SPAC has landed, and it’s one featuring Purdue Pharma’s former CEO, Mark Timney.
Blade Therapeutics announced its plans Monday to reverse merge with the bluntly named Biotech Acquisition Company in a $... |
| 08.11.2021 | AI upstart grabs $40M launch round; Sanofi backs a gene therapy player; Axsome hits a snag at the FDA | Boston AI-focused biotech DeepCure closed a $40 million Series A, according to a company announcement this morning — adding more than five times the amount of money the company had before: from $7 million raised since the co... |
| 20.10.2021 | Sartorius : grows dynamically and profitably - Substantial double-digit increases in sales and earnings | GÖTTINGEN, Germany, Oct. 20, 2021 /PRNewswire/ -- The life science group Sartorius has continued to grow dynamically and profitably. For the nine-month reporting period of 2021, the company listed on the DAX since September recorded signifi... |
| 20.10.2021 | Sartorius : Conference Call 9M|2021 Presentation | Conference Call
9M 2021 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech | October 20, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius and the Sartorius ... |
| 20.10.2021 | Sartorius : grows dynamically and profitably | The life science group Sartorius has continued to grow dynamically and profitably. For the nine-month reporting period of 2021, the company listed on the DAX since September recorded significant double‑digit growth rates in sales and earnin... |
| 20.10.2021 | Sartorius Stedim Biotech : grows dynamically and profitably – Substantial... | Press Release
Göttingen, October 20, 2021
Sartorius grows dynamically and profitably - Substantial double-digit increases in sales and earnings
Order intake up 72.3 percent; sales revenue up 53.9 percent; underlying EBITDA margin 34.3 per... |
| 20.10.2021 | Sartorius Stedim Biotech : Earnings Release 9M|2021 | Press Release
Aubagne, October 20, 2021
Nine-month results of Sartorius Stedim Biotech
Sales revenue up 56.2 percent to 2,109 million euros; underlying EBITDA margin 36.3 percent
Dynamic and profitable organic growth; significant demand mom... |
| 20.10.2021 | Sartorius Stedim Biotech : Nine-month results of Sartorius Stedim Biotech | AUBAGNE, France, Oct. 20, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, has continued to grow dynamically and profitably. For the nine-month reporting period of 2021, the company recorded signif... |
| 20.10.2021 | Sartorius : grows dynamically and profitably – Substantial double-digit increases in sales and earnings | Sartorius grows dynamically and profitably - Substantial double-digit increases in sales and earnings
Göttingen, October 20, 2021
Order intake up 72.3 percent; sales revenue up 53.9 percent; underlying EBITDA margin 34.3 percent
Both divisi... |
| 27.09.2021 | Sartorius to expand Business Operations in North America | – 130,000-square-foot plant in Ann Arbor, Michigan
– 160 new jobs to be created from initiative
– Opening of facility by year end 2023
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, i... |
| 04.09.2021 | Sartorius : To Join The DAX Blue Chip Index | GÖTTINGEN, Germany, Sept. 4, 2021 /PRNewswire/ -- The life science group Sartorius will be admitted to the German DAX blue chip index. After the market closes on September 17, 2021, Sartorius preference shares will be included in the calcul... |
| 21.07.2021 | Sartorius Stedim Biotech : Half-Year Report H1|2021 | Sartorius Stedim Biotech First-Half Financial Report Key Figures for the First Half and Second Quarter of 2021 1
Key Figures for the First Half and Second Quarter of 2021
in millions of € unless otherwise specified 6 months 2021 6 months 20... |
| 21.07.2021 | Sartorius continues on its fast growth trajectory - significant double-digit increases in sales and earnings
USA - English Deutschland - Deutsch | |
| 21.07.2021 | Sartorius Stedim Biotech : Half-year results of Sartorius Stedim Biotech | Press Release
Aubagne, July 21, 2021
Half-year results of Sartorius Stedim Biotech
Sales revenue up 61.1 percent to 1,352 million euros; underlying EBITDA margin 36.1 percent
Dynamic organic growth; added momentum from pandemic-related busi... |
| 21.07.2021 | Half-year results of Sartorius Stedim Biotech
USA - English France - Français | |
| 21.07.2021 | Sartorius Stedim Biotech : continues on its fast growth trajectory – significant... | Press Release
Göttingen, July 21, 2021
Sartorius continues on its fast growth trajectory - significant double-digit increases in sales and earnings
Order intake up 82.4 percent; sales revenue up 60.1 percent; underlying EBITDA margin 34.1 p... |
| 21.07.2021 | Sartorius : continues on its fast growth trajectory - significant double-digit increases in sales and earnings | GÖTTINGEN, Germany, July 21, 2021 /PRNewswire/ -- The life science Group Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake1.
... |
| 21.07.2021 | Sartorius Stedim Biotech : Conference Call H1|2021 Presentation | Conference Call
H1 2021 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech | July 21, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Ste... |
| 16.07.2021 | Sartorius Stedim Biotech : Financial Data H1|2021 | Overview
Sartorius Stedim Biotech
Key Figures for the First Half of 2021
in millions of € unless otherwise specified
6-mo. 2021 6-mo. 2020 ∆ in % ∆ in % cc1
Sales Revenue and Order Intake
Order intake 1,889.9 1,048.7 80.2 87.4
Sales revenue... |
| 05.07.2021 | Sartorius Stedim Biotech provides preliminary first-half financial key figures and raises forecast for 2021
USA - English France - Français | |
| 05.07.2021 | Sartorius provides preliminary first-half financial key figures and raises forecast for 2021
USA - English Deutschland - Deutsch | |
| 28.05.2021 | SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech : expands production capacities for products for the... | Press Release
Ajdovscina, Slovenia, May 28, 2021
Sartorius expands production capacities for products for the purification of vaccines and therapeutics in Slovenia
Ribbon cutting attended by the Prime Minister of the Republic of Slovenia, J... |
| 29.04.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : Conference Call Q1|2021 Presentation PDF | 447.3 KB | April 29, 2021 | Conference Call Q1 2021 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
April 21, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Sted... |
| 29.04.2021 | Sartorius : Conference Call Q1|2021 Presentation PDF | 447.3 KB | April 29, 2021 | Conference Call Q1 2021 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
April 21, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Sted... |
| 21.04.2021 | Sartorius with first-quarter uptick in sales and earnings
USA - English Deutschland - Deutsch | |
| 21.04.2021 | First-quarter results of Sartorius Stedim Biotech
USA - English France - Français | |
| 21.04.2021 | SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech : First-quarter results of Sartorius Stedim Biotech | AUBAGNE, France, April 21, 2021 /PRNewswire/ --
Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent
A good 23 percentage points of growth contributed by the coronavirus pandemic
Accelerated expansion of... |
| 21.04.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : with first-quarter uptick in sales and earnings | GÖTTINGEN, Germany, April 21, 2021 /PRNewswire/ --
Order intake up 89.2 percent; sales revenue up 61.6 percent;
underlying EBITDA margin 33.3 percent
20 percentage points of sales growth influenced by the coronavirus pandemic
Accelerated ex... |
| 21.04.2021 | Sartorius Stedim Biotech : First-quarter results of Sartorius Stedim Biotech | AUBAGNE, France, April 21, 2021 /PRNewswire/ --
Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent
A good 23 percentage points of growth contributed by the coronavirus pandemic
Accelerated expansion of... |
| 21.04.2021 | Sartorius : with first-quarter uptick in sales and earnings | GÖTTINGEN, Germany, April 21, 2021 /PRNewswire/ --
Order intake up 89.2 percent; sales revenue up 61.6 percent;
underlying EBITDA margin 33.3 percent
20 percentage points of sales growth influenced by the coronavirus pandemic
Accelerated ex... |
| 19.04.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements | DGAP Preliminary announcement financial reports: SARTORIUS AG / Preliminary announcement on the disclosure of financial statements
Sartorius AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statemen... |
| 16.04.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : expands in the UK by relocating to a new facility for... | DateApr 16, 21
Sartorius AG
Financial News
Press Release
Sartorius expands in the UK by relocating to a new facility for downstream processing equipment
Havant, UK, April 16, 2021
New 58,000-square-foot facility will simplify and accelerate... |
| 30.03.2021 | Sartorius launches the Octet® R Series for label-free, real-time molecular analysis | Sartorius launches the Octet® R Series for label-free, real-time molecular analysis
30-03-2021
The Life Science group Sartorius has launched the new high-performance Octet® R series of systems, the latest improvement in the company’s line o... |
| 30.03.2021 | Sartorius launches the Octet® R Series for label-free, real-time molecular analysis | The Life Science group Sartorius has launched the new high-performance Octet® R series of systems, the latest improvement in the company’s line of label-free analytical products.
With three different models to choose from, users can strike ... |
| 18.03.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : raises forecast for the full year of 2021 | Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius has raised its growth forecast for both divisions and, therefore, for the entire Group for... |
| 18.03.2021 | Sartorius Stedim Biotech : increases its full-year 2021 guidance | Press release
Disclosure of inside information according to Article 17 MAR
Sartorius Stedim Biotech increases its full-year 2021 guidance
Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to contin... |
| 18.03.2021 | SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech : increases its full-year 2021 guidance | Press release
Disclosure of inside information according to Article 17 MAR
Sartorius Stedim Biotech increases its full-year 2021 guidance
Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to contin... |
| 18.03.2021 | Sartorius : raises forecast for the full year of 2021 | Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius has raised its growth forecast for both divisions and, therefore, for the entire Group for... |
| 18.03.2021 | Sartorius Stedim Biotech increases its full-year 2021 guidance
USA - English
France - Français | |
| 18.02.2021 | Sartorius Stedim Biotech : looks back on a very successful 2020 and... | Press Release
Aubagne, February 18, 2021
Sartorius Stedim Biotech looks back on a very successful 2020 and expects further strong growth
Sales revenue up 34.6 percent; underlying EBITDA margin at 31.7 percent
Outlook for the current yea... |
| 18.02.2021 | Sartorius : Conference Call FY|2020 Presentation | Disclaimer
This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forwa... |
| 18.02.2021 | SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech : looks back on a very successful 2020 and... | Press Release
Aubagne, February 18, 2021
Sartorius Stedim Biotech looks back on a very successful 2020 and expects further strong growth
Sales revenue up 34.6 percent; underlying EBITDA margin at 31.7 percent
Outlook for the current yea... |
| 18.02.2021 | Sartorius looks back on a very successful 2020 and expects further strong growth
USA - English
Deutschland - Deutsch | |
| 18.02.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : Conference Call FY|2020 Presentation | Disclaimer
This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forwa... |
| 18.02.2021 | Sartorius Stedim Biotech looks back on a very successful 2020 and expects further strong growth
USA - English
France - Français | |
| 18.02.2021 | Sartorius Stedim Biotech : looks back on a very successful 2020 and expects further strong growth | AUBAGNE, France, Feb. 18, 2021 /PRNewswire/ --
Sales revenue up 34.6 percent; underlying EBITDA margin at 31.7 percent
Outlook for the current year: sales projected to increase by 20 percent to 26 percent
Accelerated and greater ramp-up of ... |
| 18.02.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : looks back on a very successful 2020 and expects further strong growth | GOTTINGEN, Germany, Feb. 18, 2021 /PRNewswire/ -- The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report. Group sales revenue surged by 30.2 percent to nearly 2,336 million euros in... |
| 18.02.2021 | Sartorius : looks back on a very successful 2020 and expects further strong growth | GOTTINGEN, Germany, Feb. 18, 2021 /PRNewswire/ -- The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report. Group sales revenue surged by 30.2 percent to nearly 2,336 million euros in... |
| 18.02.2021 | SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech : looks back on a very successful 2020 and expects further strong growth | AUBAGNE, France, Feb. 18, 2021 /PRNewswire/ --
Sales revenue up 34.6 percent; underlying EBITDA margin at 31.7 percent
Outlook for the current year: sales projected to increase by 20 percent to 26 percent
Accelerated and greater ramp-up of ... |
| 18.02.2021 | Sartorius Stedim Biotech : looks back on a very successful 2020 and expects... | Press Release
Göttingen, February 18, 2021
Sartorius looks back on a very successful 2020 and expects further strong growth
Order intake up 49.0 percent; sales revenue up 30.2 percent; underlying EBITDA margin at 29.6 percent
Outlook fo... |
| 18.02.2021 | SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech : looks back on a very successful 2020 and expects... | Press Release
Göttingen, February 18, 2021
Sartorius looks back on a very successful 2020 and expects further strong growth
Order intake up 49.0 percent; sales revenue up 30.2 percent; underlying EBITDA margin at 29.6 percent
Outlook fo... |
| 28.01.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : Conference Call FY|2020 Presentation PDF | 692.2 KB | Januar 28, 2021 | Conference Call
Preliminary Full-Year 2020 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
January 27, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius a... |
| 28.01.2021 | Sartorius : Conference Call FY|2020 Presentation PDF | 711.4 KB | Januar 28, 2021 | Conference Call
Preliminary Full-Year 2020 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
January 27, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius a... |
| 28.01.2021 | Sartorius : Conference Call FY|2020 Presentation PDF | 692.2 KB | Januar 28, 2021 | Conference Call
Preliminary Full-Year 2020 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
January 27, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius a... |
| 28.01.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : Conference Call FY|2020 Presentation PDF | 711.4 KB | Januar 28, 2021 | Conference Call
Preliminary Full-Year 2020 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
January 27, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius a... |
| 27.01.2021 | SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech : with exceptionally strong growth in 2020 and a further increase in profitability | AUBAGNE, France, Jan. 27, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded exceptionally strong growth in 2020 that was driven by strong organic development, several acquisitions and addit... |
| 27.01.2021 | SARTORIUSADR : Sartorius closes 2020 with strong growth to well over 2 billion euros and a further increase in profitability | GOTTINGEN, Germany, Jan. 27, 2021 /PRNewswire/ -- The life science group Sartorius recorded high growth according to preliminary figures in 2020 due to strong organic development, several acquisitions and the additional momentum from busine... |
| 27.01.2021 | Sartorius Stedim Biotech : closes 2020 with strong growth to well over 2 billion... | The life science group Sartorius recorded high growth according to preliminary figures in 2020 due to strong organic development, several acquisitions and the additional momentum from business related to the coronavirus pandemic. The Group ... |
| 27.01.2021 | Sartorius closes 2020 with strong growth to well over 2 billion euros and a further increase in profitability
USA - English
Deutschland - Deutsch | |
| 27.01.2021 | Sartorius Stedim Biotech : with exceptionally strong growth in 2020 and a further increase in profitability | AUBAGNE, France, Jan. 27, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded exceptionally strong growth in 2020 that was driven by strong organic development, several acquisitions and addit... |
| 27.01.2021 | SARTORIUS AKTIENGESELLSCHAFT
Sartorius : Conference CallPreliminary Full-Year 2020 Results Presentation | Conference Call
Preliminary Full-Year 2020 Results
Joachim Kreuzburg, Rainer Lehmann
Sartorius | Sartorius Stedim Biotech
January 27, 2021
Disclaimer
This presentation contains statements concerning the future performance of the Sartorius a... |
